Elisabeth Leiderman
Direktor/Vorstandsmitglied bei BLUEBIRD BIO, INC.
Vermögen: 20 320 $ am 30.04.2024
Ursprung des Netzwerks ersten Grades von Elisabeth Leiderman
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Biotechnology | 35 | |
| Public Company | Biotechnology | 23 | |
| Public Company | Pharmaceuticals: Major | 21 | |
| Public Company | Biotechnology | 12 | |
Complexa, Inc.
 Complexa, Inc. Pharmaceuticals: MajorHealth Technology Complexa, Inc. operates as a biopharmaceutical company which engages on discovering and developing therapies for the treatment of severe and life-threatening fibrosis and inflammatory diseases. The firm focuses on two therapeutic areas: focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH), two rare diseases that can compromise the normal function of the kidney and the heart. The company was founded by Bruce A. Freeman, Raymond A. Miller, and Margaret M. Tarpey in 2008 and is headquartered in Berwyn, PA.
9
| Extinct | Pharmaceuticals: Major | 9 |
Nomura Securities, Inc.
3
| Private Company | 3 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Elisabeth Leiderman
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| 2SEVENTY BIO, INC. | Pharmaceuticals: Major | Director/Board Member Chairman Chief Executive Officer Human Resources Officer Director/Board Member Director/Board Member Investor Relations Contact Director/Board Member Director/Board Member Director/Board Member | |
Autolus Ltd.
 Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member Chairman Chief Executive Officer Director/Board Member Director/Board Member Director/Board Member Founder | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Undergraduate Degree Undergraduate Degree Corporate Officer/Principal Undergraduate Degree Corporate Officer/Principal | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Sales & Marketing Corporate Officer/Principal Director of Finance/CFO Comptroller/Controller/Auditor Corporate Officer/Principal | |
| University of Pennsylvania | College/University | Graduate Degree Undergraduate Degree Doctorate Degree Graduate Degree Doctorate Degree | |
| CHECKPOINT THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Chairman Chief Executive Officer Corporate Secretary | |
| JOHNSON & JOHNSON | Pharmaceuticals: Major | Director/Board Member Chairman Corporate Officer/Principal Corporate Officer/Principal | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree Doctorate Degree Corporate Officer/Principal Corporate Officer/Principal | |
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Medical/Nursing Services | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
| MUSTANG BIO, INC. | Pharmaceuticals: Major | Director/Board Member Chairman Director of Finance/CFO Corporate Secretary | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Sales & Marketing Chief Tech/Sci/R&D Officer Director/Board Member Corporate Officer/Principal | |
| KERYX BIOPHARMACEUTICALS | Pharmaceuticals: Major | Founder Chief Executive Officer Chairman Director/Board Member | |
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Biotechnology | Director/Board Member Chief Executive Officer Director/Board Member General Counsel | |
| University of Cambridge | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree Graduate Degree | |
| AVENUE THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Executive Officer Corporate Secretary | |
| Yale University | College/University | Doctorate Degree Doctorate Degree Undergraduate Degree | |
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal Director/Board Member | |
| SURFACE ONCOLOGY, INC. | Biotechnology | Chief Executive Officer Chairman Director/Board Member | |
Pharmaceutical Research & Manufacturers of America
 Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Edimer Pharmaceuticals, Inc.
 Edimer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edimer Pharmaceuticals, Inc. provides biopharmaceutical products for improving the health and quality of life of families living with XLHED. It has developed EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), which is a rare orphan disease that causes symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. The company was founded by Pascal Schneider and Olivier Gaide in 2009 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | President Corporate Officer/Principal Corporate Officer/Principal | |
Vtesse, Inc.
 Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD. | Biotechnology | Director/Board Member Founder Corporate Officer/Principal | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
ImClone LLC
 ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Biotechnology | Chief Tech/Sci/R&D Officer Chief Executive Officer Chief Executive Officer | |
| BIOGEN INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chairman | |
| GENTIUM S.P.A. (ADR) | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director of Finance/CFO | |
| VERASTEM, INC. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| University of California, Los Angeles | College/University | Corporate Officer/Principal Graduate Degree Undergraduate Degree | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| ORIGO ACQUISITION CORP | Financial Conglomerates | Chief Executive Officer Chairman Chief Operating Officer | |
| Harvard Medical School | College/University | Doctorate Degree Corporate Officer/Principal Corporate Officer/Principal | |
Caelum Biosciences, Inc.
 Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| TG THERAPEUTICS, INC. | Pharmaceuticals: Major | Founder Chief Executive Officer Director/Board Member | |
Abingworth LLP
 Abingworth LLP Investment ManagersFinance Abingworth LLP (Abingworth) is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. Abingworth LLP became part of The Carlyle Group Inc. (NASDAQ: CG) on 3rd August 2022. | Investment Managers | Director/Board Member Private Equity Investor | |
Proclara Biosciences, Inc.
 Proclara Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| New York University School of Medicine | College/University | Corporate Officer/Principal Doctorate Degree | |
| ALNYLAM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| Georgetown University | College/University | Masters Business Admin Undergraduate Degree | |
| ANNEXON, INC. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| EPIGENOMICS AG | Medical Specialties | Director/Board Member Director/Board Member | |
| BLACK DIAMOND THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| ARVINAS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Corporate Officer/Principal Private Equity Investor | |
| Bentley University | College/University | Graduate Degree Undergraduate Degree | |
Otsuka Pharmaceutical Development & Commercialization, Inc.
 Otsuka Pharmaceutical Development & Commercialization, Inc. Pharmaceuticals: MajorHealth Technology Part of Otsuka Holdings Co., Ltd., Otsuka Pharmaceutical Development & Commercialization, Inc. is a healthcare company that was founded in 2007. The company is based in Princeton, NJ. The company is driven by their purpose and defined by their beliefs. | Pharmaceuticals: Major | Chairman Corporate Officer/Principal |
Statistik
International
| Vereinigte Staaten | 43 |
| Vereinigtes Königreich | 4 |
| Schweiz | 3 |
| Norwegen | 2 |
| Italien | 2 |
Sektoral
| Health Technology | 34 |
| Consumer Services | 11 |
| Finance | 6 |
| Health Services | 2 |
| Commercial Services | 2 |
Operativ
| Director/Board Member | 502 |
| Corporate Officer/Principal | 235 |
| Independent Dir/Board Member | 165 |
| Chairman | 112 |
| Chief Executive Officer | 90 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| John Johnson | 40 |
| Peter Thompson | 39 |
| Kapil Dhingra | 39 |
| Eric Rowinsky | 36 |
| Martin Murphy | 33 |
| Daniel Lynch | 32 |
| William Young | 32 |
| Bobby Sandage | 29 |
| Malcolm Hoenlein | 28 |
| Michael Weiss | 25 |
| Wendy Dixon | 25 |
| John Berriman | 24 |
| Lindsay Rosenwald | 23 |
| Sara Nayeem | 23 |
| Karin Hehenberger | 21 |
- Börse
- Insiders
- Elisabeth Leiderman
- Unternehmensverbindungen
